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Abstract
Introduction: Anti-carbamylated protein (anti-CarP) antibodies have been described in rheumatoid arthritis (RA) and
arthralgia patients at risk of developing RA. To what extent these autoantibodies are specific for RA is unknown. Therefore,
we investigated the diagnostic performance of the presence of anti-CarP antibodies for RA in a setting of early arthritis.
Methods: Anti-CarP antibodies were detected using carbamylated fetal calf serum as substrate. Anti-CCP2 antibodies
were measured using enzyme-linked immunosorbent assay and immunoglobulin M (IgM) rheumatoid factor (RF) as part
of routine care. Sera were derived from patients in the Leiden Early Arthritis Clinic cohort obtained at inclusion.
Test characteristics were determined using the fulfillment of the 2010 RA criteria after 1 year as outcome.
Results: In total 2086 early arthritis patients were studied regarding the presence of anti-CarP antibodies. We
observed that the sensitivity and specificity of the presence of anti-CarP antibodies for RA were 44 % and 89 %,
respectively. As a reference, sensitivity and specificity of the presence of anti-CCP2 antibodies were 54 % and 96 %,
respectively, and of IgM-RF 59 % and 91 %. Patients harboring anti-CarP antibodies not classified as RA were mainly
diagnosed with undifferentiated arthritis and less frequently reactive arthritis and psoriatic arthritis.
Conclusion: Anti-CarP antibodies are predominantly present in RA but can also be detected in other forms of arthritis.
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Introduction
Rheumatoid arthritis (RA) is a chronic, systemic auto-
immune disease affecting synovial joints. RA can be classi-
fied using the 2010 American College of Rheumatology/
European League Against Rheumatism classification
criteria (2010 ACR/EULAR criteria) for RA [1]. In
this quantitative system points can be obtained from:
joint involvement, autoantibodies, acute phase reactants
and duration of symptoms [1]. Anti-citrullinated protein
antibodies (ACPA) and rheumatoid factor (RF) are in-
cluded in the 2010 ACR/EULAR criteria because of their
high sensitivity and specificity in RA patients [1]. The
presence of either ACPA or RF contributes 2 points and a
‘high’ level of either ACPA or RF contributes 1 extra point.
The sensitivity of ACPA (~67 %) for RA is comparable to
immunoglobulin (Ig)M-RF (~69 %) while their specificity
(~95 %) is higher than that of IgM-RF (~85 %) [2]. Re-
cently we identified anti-carbamylated protein (anti-CarP)
antibodies in both anti-cyclic citrullinated peptide 2 (anti-
CCP2) antibody-positive and -negative RA patients [3–5].
Anti-CarP antibodies target proteins that are modified
through a post-translational modification named carbamy-
lation [6]. Carbamylation is mediated by cyanate which
mainly modifies lysine residues. The level of cyanate is in
equilibrium with urea and can be increased, for example,
during renal failure, during smoking and during inflam-
mation through a mechanism depending on myeloperoxi-
dase [7], the level of which is increased in RA patients [8].
The process of carbamylation, like citrullination, is not
restricted to RA but the formation of antibodies against
these modified proteins is. Whereas the presence of
anti-CCP2 antibodies is strongly associated with the
HLA-shared epitope (SE) alleles and smoking, there is
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no association between anti-CarP antibodies and smoking
after correction for anti-CCP2 antibodies [4]. Anti-CarP
antibodies are also not associated with HLA-SE following
correction for anti-CCP2 antibodies, but is possibly with
HLA-DR*3 [4]. How anti-CarP antibodies would contrib-
ute to arthritis is unknown but may involve immune
complex formation between anti-CarP antibodies and
carbamylated proteins in the joint.
The presence of anti-CarP antibodies in anti-CCP2
antibody-negative RA patients was associated with in-
creased disease activity [5] and with more severe joint
damage [3, 9, 10]. Anti-CarP antibodies were also found
in about 40 % of RF and/or ACPA-positive arthralgia pa-
tients, who have joint pain without clinically detectable
arthritis [11]. Comparable to ACPA, anti-CarP anti-
bodies are also independently associated with the risk of
developing RA in these arthralgia patients [11]. Anti-
CarP antibodies can be detected in serum many years
before the clinical diagnosis of RA [10, 12, 13] and are
independently associated with increased joint damage at
the baseline of RA diagnosis [10].
Since anti-CarP antibodies have prognostic value in
RA patients we are interested in their diagnostic per-
formance for RA in comparison to ACPA and RF in a
clinically relevant setting of early arthritis.
Methods
Patients
We analyzed baseline sera of patients included in the
Leiden Early Arthritis Clinic (EAC) cohort that contains
patients with arthritis of at least one joint and a symp-
tom duration less than 2 years [14]. We measured the
presence of anti-CarP, anti-CCP2 antibodies and IgM-RF
in the sera of 2086 unselected consecutive EAC sera that
were collected between 1993 and 2011. The outcome
was the diagnosis after 1 year of disease; we classified
RA by strictly applying the 2010 ACR/EULAR criteria.
[1]. Disease categories containing less than 20 patients
were merged as “other” rheumatic diseases. The control
sera were collected from healthy, non-arthritic inhabi-
tants of the Leiden area. The protocols were approved
by the Leiden University Medical Center ethics commit-
tee and informed consent was obtained.
Anti-CarP, anti-CCP2 and IgM-RF measurements
Anti-CarP antibodies were detected using carbamylated
fetal calf serum as antigen as described previously
[3, 10, 12]. IgM-RF was determined as part of rou-
tine care and anti-CCP2 enzyme-linked immunosorb-
ent assay (ELISA; Euro-Diagnostica) was performed
following the manufacturer’s instructions. The cut-
offs for the anti-CarP antibody ELISA was set as the
mean plus two times the standard deviation (SD) of
the healthy controls.
Statistical analysis
Statistical analysis was performed with SPSS version
20.0 (SPSS Inc., Chicago, USA). Dunn’s multiple com-
parison test was performed to compare the levels of
anti-CarP antibodies between diagnoses. Chi-square
test with multiple testing correction was performed to
compare the percentages of anti-CarP antibodies,
anti-CCP2 antibodies and IgM-RF-positive patients in
different types of arthritis. The sensitivity, specificity,
positive predictive value, negative predictive value,
positive likelihood ratio (LR+) and negative likelihood
ratio (LR–) of anti-CarP antibodies for RA were
calculated. The area under the receiver operator char-
acteristic curve (AUC) of anti-CarP antibodies for RA
was calculated. P values below 0.05 were considered
statistically significant.
Results
Sensitivity and specificity of anti-CarP antibodies for RA
The Leiden EAC cohort comprises patients with sev-
eral forms of recent-onset arthritis which can be en-
countered in the setting of an outpatient clinic [14].
Of the 2086 patients analyzed, 969 patients (47 %)
were classified with RA and 493 (24 %) patients as
undifferentiated arthritis (UA). A complete overview
of the diagnoses is presented in Fig. 1. We observed
that anti-CarP antibodies were present in 26 % of all
patients analyzed and in 2 % of the healthy controls.
The test characteristics were subsequently determined
with RA according to the 2010 criteria as outcome.
The sensitivity of detection of anti-CarP antibodies in
RA patients was 44 % and the specificity of anti-CarP
antibodies for RA was 89 %. In the ACPA-negative
stratum the sensitivity and specificity were 12 % and
91 %, respectively.
Diagnostic performance of anti-CarP antibodies in relation
to anti-CCP2 and RF for diagnosing RA
The performance of detecting anti-CarP antibodies for
diagnosing RA was compared to that of anti-CCP2 and
RF. We observed a sensitivity for RA of 44 %, 54 % and
59 % for anti-CarP, anti-CCP2 and RF, respectively, with
a specificity of 89 %, 96 % and 91 %, respectively
(Table 1). The LR+ of anti-CarP antibodies for RA was
4.2 which was lower than the LR+ of anti-CCP2 anti-
bodies (12.9) and IgM-RF (6.9). The LR– for anti-CarP
antibodies (0.62) was slightly higher compared to anti-
CCP2 antibodies (0.48) and IgM-RF (0.44). Within the
total study population, the AUC of anti-CarP positivity
was 0.67 (95 % confidence interval (CI) 0.64–0.69;
Fig. 2a). In anti-CCP2-negative early arthritis patients it
was 0.52 (95 % CI 0.48–0.55) suggesting that knowledge
on anti-CarP autoantibody status added only limited
information for diagnosing RA.
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Occurrence of anti-CarP antibodies in other forms of arthritis
In Fig. 1 the level of anti-CarP antibodies in the sera of
individual types of early arthritis are depicted. Anti-CarP
antibodies were most prevalent in RA, but were also
detected in other forms of early arthritis (Table 2), simi-
lar to ACPA and RF. This does not seem to be restricted
to certain forms of early arthritis, possibly with the
exception of pseudogout (Table 2). Analyzing the anti-
CarP-positive non-RA early arthritis patients (n = 120)
separately revealed that these patients were mainly diag-
nosed as UA (42 %), reactive arthritis (9 %), psoriatic
arthritis (9 %) or peripheral spondyloarthritis (8 %).
Comparing the levels of the anti-CarP antibodies in
anti-CarP-positive patients across the different forms of
early arthritis revealed that the levels were significantly
higher in RA compared to the non-RA conditions
(p < 0.05 in all conditions). However, high levels were also
detected occasionally in other forms of arthritis (Fig. 1).
Even though anti-CCP2 antibodies and IgM-RF are
both part of the 2010 classification criteria, some pa-
tients positive for these autoantibodies had diagnoses
other than RA (Table 2). We did not observe a non-RA
condition that harbored significantly more anti-CarP,
anti-CCP2 antibodies or IgM-RF-positive patients com-
pared to any other non-RA conditions (p > 0.05 in all
conditions). The distribution of anti-CarP, anti-CCP2
antibodies and IgM-RF in RA and other patients is
shown in Fig. 2b and c. In the RA patients the three
antibodies analyzed frequently occur together, or as
combinations of two autoantibodies, whereas in the
non-RA group there are fewer patients that display
double or triple positivity.
Presence of one, two or three autoantibodies and
diagnosis of RA
When comparing the presence of one, two or three
autoantibodies to the patients with zero autoantibodies
we observed that with increasing numbers of autoanti-
bodies the odds ratio (OR) of having the diagnosis RA
highly increased (Fig. 2d). For the group with one auto-
antibody the OR is 3.8 (95 % CI 2.9–5.0), for two auto-
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Fig. 1 Distribution of anti-CarP antibodies in sera of patients suffering from early arthritis. The number of controls and patients with each disease
and the levels of anti-CarP antibodies in the serum of each individual are shown. Horizontal dashed line indicates cut-off. Anti-CarP Anti-carbamylated
protein, OA Inflammatory osteoarthritis, PsA Psoriatic arthritis, Ps-Gout Pseudogout, RA Rheumatoid arthritis, ReA Reactive arthritis (bacterial and viral),
RS3PE Remitting seronegative symmetrical synovitis with pitting edema, Sarc Sarcoidosis, SpA Spondylarthropathy with peripheral arthritis,
UA Undifferentiated arthritis
Table 1 The test characteristics of different autoantibodies in RA
Sensitivity Specificity PPV NPV LR+ LR–
Anti-CarP 44 % 89 % 78 % 65 % 4.2 0.62
Anti-CCP2 54 % 96 % 94 % 64 % 12.9 0.48
IgM-RF 59 % 91 % 86 % 72 % 6.9 0.44
Anti-CarP in anti-CCP-negative patient 12 % 91 % 37 % 71 % 1.3 0.97
A comparison is provided on the test characteristics of anti-CarP, anti-CCP and IgM RF for diagnosing RA. In addition the performance of anti-CarP in the
CCP2-negative stratum is analyzed
Anti-CarP Anti-carbamylated protein, Anti-CCP2 Anti-cyclic citrullinated peptide 2, IgM-RF Immunoglobulin M-rheumatoid factor, LR+ Positive likelihood ratio,
LR– Negative likelihood ratio, NPV Negative predictive value, PPV Positive predictive value, RA Rheumatoid arthritis
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for three autoantibodies to 112.2 (95 % CI 52.4–240.5),
with all the groups significantly different from the zero
autoantibodies reference group (p < 0.0001).
The high ORs observed for the double and triple posi-
tives may be expected as ACPA and RF are part of the
2010 criteria. However, it is important to note that com-
paring the ACPA and RF double-positive patients (OR
36.7 (95 % CI 16.9–79.9)) to the ACPA, RF and anti-
CarP triple-positive group (112.2 (95 % CI 52.4–240.5)),
there is an additional effect of OR 3.0 (95 % CI 1.1–8.9;
p = 0.04).
Discussion
Here we have analyzed the sensitivity and specificity of
detecting anti-CarP antibodies for RA in a setting of
early arthritis encountered at the rheumatology out-
patient clinic. The sensitivity of the presence of anti-
CarP antibodies for RA patients is slightly lower than
that of anti-CCP2 antibodies and IgM-RF. The specifi-
city of detection of anti-CarP antibodies is similar to
IgM-RF and is slightly lower than anti-CCP2 antibodies.
Even though anti-CCP2 antibodies and IgM-RF are both
part of the 2010 classification criteria, individuals posi-
tive for these autoantibodies are also identified in the
non-RA arthritis groups, as has also been reported
before [15–17]. Therefore, it may not be surprising that
anti-CarP antibodies, not being part of the 2010 classifi-
cation criteria, can also be present in arthritic conditions
other than RA. We have adhered very closely to the def-
inition when the 2010 classification criteria may be ap-
plied and have not considered patients for the possible
diagnosis RA if their synovitis was more likely explained
by another diagnosis [1]. Comparing the data on the
sensitivity and specificity of detection of anti-CarP anti-
bodies for RA using either the 2010 criteria or the 1987
criteria (data not shown) gave almost identical results.
The only exception was that when using the 1987 cri-
teria the presence of anti-CarP antibodies in UA patients
was significantly associated with future development of
RA independent of ACPA and RF, similar to what we
observed before for arthralgia patients [11]. When the
2010 criteria were used this was not the case (data not
shown). Patients are frequently double-positive for anti-
CCP and anti-CarP antibodies and since anti-CCP has a
more prominent role in the 2010 criteria this may ex-
plain why anti-CarP antibodies are associated with con-
version of UA to RA using the 1987 criteria but not
when using the 2010 criteria.
So far we have applied a cut-off for positivity defined
as the mean plus two times the SD of a set of healthy
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Fig. 2 Anti-CarP antibodies in relation to ACPA and IgM-RF in RA and other forms of early arthritis. a Receiver operator curve and AUC analysis of
dichotomous data of anti-CarP antibodies in the whole cohort. b Distribution of positivity for anti-CarP antibodies, anti-CCP2 antibodies and IgM-
RF in the patients diagnosed with RA. c Distribution of these autoantibodies in the patients diagnosed with the non-RA forms of early arthritis. Both b
and c are for all individuals for whom data on anti-CarP and CCP2 and RF were available (n = 934 for RA and n = 780 for non-RA). d Odds ratios for
having the diagnosis RA based on the presence of one, two or three autoantibodies relative to having zero autoantibodies. ACPA Anti-citrullinated protein
antibodies, Anti-CarP Anti-carbamylated protein, AUC Area under the curve, IgM-RF Immunoglobulin M-rheumatoid factor, RA Rheumatoid arthritis
Table 2 Prevalence of different autoantibodies in early arthritis patients with various diagnoses
RA UA ReA Gout Ps-gout PsA OA Sarc SpA RS3PE Other
anti-CarP 44 % 10 % 16 % 8 % 0 % 9 % 11 % 9 % 15 % 4 % 17 %
anti-CCP2 54 % 3 % 8 % 0 % 0 % 6 % 7 % 5 % 8 % 0 % 7 %
IgM-RF 59 % 5 % 7 % 6 % 11 % 10 % 20 % 7 % 4 % 7 % 20 %
The percentages indicate the proportion of patients positive for one of the three autoantibodies analyzed in all samples available for each of the diagnoses
Anti-CarP Anti-carbamylated protein, Anti-CCP2 Anti-cyclic citrullinated peptide 2, IgM-RF Immunoglobulin M-rheumatoid factor, OA Inflammatory osteoarthritis,
PsA Psoriatic arthritis, Ps-Gout Pseudogout, RA Rheumatoid arthritis, ReA Reactive arthritis (bacterial and viral), RS3PE Remitting seronegative symmetrical synovitis
with pitting edema, Sarc Sarcoidosis, SpA Spondylarthropathy with peripheral arthritis, UA Undifferentiated arthritis
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control sera for anti-CarP antibody ELISA [3, 11, 13]. At
the current cut-off for positivity, the AUC of anti-CarP
antibodies in the total group was 0.67, whereas in the
anti-CCP2/RF-negative group it was only 0.52. This indi-
cates that for purely diagnostic purposes the presence of
anti-CarP antibodies is not discriminating in the anti-
CCP2/RF-negative stratum. However, we have previously
been able to identify the anti-CarP positive but CCP2 nega-
tive group as a prognostically relevant group of RA patients
who were clinically distinct from the double-negative pa-
tients regarding disease activity [5] and especially joint de-
struction using our current cut-off [3], an observation now
confirmed in other studies [9, 10]. In our view, the current
definition of the cut-off is reasonable and we welcome rep-
lication of these findings in other cohorts.
The diagnosis of RA is predominantly based on clinical
observations with possible supportive information from
serology [18]. However, as we are moving forward to iden-
tifying persons in the pre-RA phase where the full clinical
picture of RA is not yet apparent, biomarkers will become
more important. We have previously shown anti-CarP
antibodies can already be present years prior to clinical on-
set of RA [10, 12, 13] and that the presence of anti-CarP
antibodies in addition to RF and ACPA provided relevant
information on future development of RA [11]. The high
OR for RA in triple-positive early arthritis patients ob-
served in the current study may suggest that triple positiv-
ity may also be used to identify future RA patients among
individuals that do not yet display clinical symptoms.
In the current study, we observed that anti-CarP anti-
bodies occur in almost all forms of early arthritis. Al-
though at lower frequencies, anti-CCP antibodies were
also detected in many other forms of arthritis (Table 2)
[15–17]. Whether or not anti-CarP-positive patients with
diagnoses other than RA have a different disease course
than the anti-CarP-negative patients with the same
diagnosis is a subject of future studies.
Conclusions
Anti-CarP antibodies are predominantly present in RA
but can also be detected in small subsets of patients
suffering from other forms of early arthritis.
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